Skip to content
MedsAcross

Medicine

Pyridostigmine 60 mg/5 mL oral solution

Available on requestPrescription onlyUS FDAGeneric name

Pyridostigmine 60 mg/5 mL oral solution is a generic prescription medicine for oral use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F), excursions permitted to 15° to 30°C (59°to 86°F).

Key facts

Active ingredient (INN)
Pyridostigmine
Brand
Sold under the generic name
Strength
60 mg/5 mL
Dosage form
Oral solution
Route
Oral
Packs
473 mL, 1 tray and 2 more
Manufacturers
Novadoz PharmaceuticalsIndiaAcella PharmaceuticalsAmneal Pharmaceuticals NYNovitium PharmaVistaPharm
Origin register
US FDA, United States
Storage
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59°to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N07AA02 Pyridostigmine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
11 March 2019
Identifiers
RxCUI 903843DailyMed set ID 0bed477f-b228-4f8d-a956-f192b1329ea0, ef78ff05-8e0f-463a-88cd-ca9a01aed76a, 9c3a5abf-e217-4292-a305-5afd12b99e95 +2NDC 72205-098, 70954-148, 69238-1731 +2Application ANDA216512, ANDA211694, ANDA212702 +1

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
473 mL in 1 bottle72205-098-72Novadoz PharmaceuticalsIndia26 September 2023
473 mL in 1 bottle42192-626-16Acella Pharmaceuticals9 October 2023
473 mL in 1 bottle69238-1731-2Amneal Pharmaceuticals NY17 January 2020
473 mL in 1 bottle70954-148-10Novitium Pharma11 March 2019
1 tray in 1 case / 10 cup, unit-dose in 1 tray / 5 mL in 1 cup, unit-dose66689-406-10VistaPharm6 January 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 6 April 1955Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Pyridostigmine 60 mg/5 mL oral solution.

Compare all 2

Other strengths and forms of Pyridostigmine

Clinical summary

Pyridostigmine is a cholinesterase inhibitor. It is available as tablets, oral solution and extended-release tablets for intravenous and parenteral use. MedsAcross supplies Pyridostigmine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Pyridostigmine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Pyridostigmine 60 mg/5 mL oral solution for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.